Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 6 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Alfasigma S.p.A. currently has 6 pending office actions in the Biotechnology & Pharmaceuticals technology area. These are handled by 6 distinct examiners, meaning each pending matter is under the review of a different individual. This distribution requires a case-by-case strategy for each of the 6 pending office actions. The lack of examiner overlap means that no single individual's preferences dominate the portfolio.
The portfolio is spread across 6 distinct art units, matching the number of examiners and pending actions. GOUGH, TIFFANY MAUREEN is the busiest examiner with 1 pending office action. The perfect alignment between 6 actions, 6 examiners, and 6 art units suggests that each pending matter represents a distinct technical sub-field within the pharmaceutical sector. This diversity in art units indicates a broad range of biotechnological research currently being prosecuted. Managing 6 pending office actions across 6 different art units requires a versatile approach to patent prosecution. Each of the 6 pending office actions must be advanced independently.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| Double-patenting + other | 4 (67%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GOUGH, TIFFANY MAUREEN | 1 | 31.7% | +46.5% |
| KUCKLA, ANNA GRACE | 1 | 53.8% | +51.3% |
| CHHAY, BONIRATH | 1 | 62.5% | +0.0% |
| XU, QING | 1 | 50.9% | +55.2% |
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
| PECKHAM, RICHARD GRANT | 1 | 68.1% | +36.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17998534 | COMPOSITION COMPRISING METHYLFOLATE | KASSA, TIGABU | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | PECKHAM, RICHARD GRANT | 26d |
| 18493221 | USE OF A COMPOSITION COMPRISING MICROORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTYRIC ACID, FOLIC ACID OR NIACIN AND/OR DECREASE THE INTESTINAL PRODUCTION OF SUCCINIC ACID | XU, QING | 63d |
| 18865784 | LACTICASEIBACILLUS PARACASEI DG(R) CNCM I-1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS | GOUGH, TIFFANY MAUREEN | — |
| 18800808 | FARNESOID X RECEPTOR MODULATORS | KUCKLA, ANNA GRACE | — |
| 17998534 | COMPOSITION COMPRISING METHYLFOLATE | KASSA, TIGABU | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1626 | 1 |
| 1645 | 1 |
| 1656 | 1 |
| 1619 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18865784 | LACTICASEIBACILLUS PARACASEI DG(R) CNCM I-1572 DSM 34154 FOR USE IN A METHOD OF TREATING DYSBIOSIS IN PATIENTS WITH IBS | GOUGH, TIFFANY MAUREEN | 1651 | §102§112DP | Non-Final OA | — | Pending | Nov 14, 2024 |
| 18800808 | FARNESOID X RECEPTOR MODULATORS | KUCKLA, ANNA GRACE | 1626 | §112DP | Non-Final OA | — | Pending | Aug 12, 2024 |
| 18579158 | USE OF LACTOBACILLUS PARACASEI BACTERIAL STRAINS IN THE TREATMENT OF NEWBORNS | CHHAY, BONIRATH | 1645 | §103§112DP | Final Rejection | 2d overdue | Pending | Jan 12, 2024 |
| 18493221 | USE OF A COMPOSITION COMPRISING MICROORGANISMS TO INCREASE THE INTESTINAL PRODUCTION OF BUTYRIC ACID, FOLIC ACID OR NIACIN AND/OR DECREASE THE INTESTINAL PRODUCTION OF SUCCINIC ACID | XU, QING | 1656 | §103 | Final Rejection | 63d | Pending | Oct 24, 2023 |
| 17998534 | COMPOSITION COMPRISING METHYLFOLATE | KASSA, TIGABU | 1619 | §103§112 | Non-Final OA | — | Pending | Nov 11, 2022 |
| 17342057 | METHODS AND INTERMEDIATES FOR THE PREPARATION OF BILE ACID DERIVATIVES | PECKHAM, RICHARD GRANT | 1627 | §103DP | Final Rejection | 26d | Pending | Jun 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlfasigma S.p.A. has 6 pending office actions as of October 2026, spread across 6 art units and 6 examiners.
Tiffany Maureen Gough has the most, with 1 of Alfasigma S.p.A.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
